Condition

Relapsed / Refractory AML clinical trials and research

• 2Clinical trials
• 1Country

All recruiting trials (2)

• Metronomic Decitabine-Cedazuridine and Venetoclax therapy for relapsed/refractory AML and high-risk blood cancers

  This phase 2 trial tests a metronomic decitabine-cedazuridine plus venetoclax regimen versus azacitidine plus venetoclax in adults with relapsed/refractory AML or high-risk MDS/MPN.

  Recruiting Phase 2 Virginia Commonwealth University · Richmond, Virginia · NCT07710534

• Olutasidenib after venetoclax in IDH1-mutated relapsed/refractory AML

  This study tests whether olutasidenib can help adults with IDH1-mutated AML that has relapsed or not responded to venetoclax-based therapy.

  Recruiting Phase 2 Hoosier Cancer Research Network · Winston-Salem, North Carolina · NCT07471841

Related topics

Quick answers

How many Relapsed / Refractory AML clinical trials are recruiting right now?

2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →